Preface

Targeted therapy and non-small cell lung cancer: a new era!

Non-small cell lung cancer (NSCLC) represents the principal cause of death for cancer worldwide, with an incidence of 1,350,000 new diagnosis each year and mortality of 1,180,000 deaths each year (1). In the last 10 years, predictive molecular pathology and precision medicine led to a revolution in NSCLC clinical management, encouraging the incorporation of tumor genotyping into therapeutic decision making and the development of new therapeutic options, such as first and second generations of tyrosine kinase inhibitors (TKIs) molecules for oncogene addicted NSCLC patients (e.g., *EGFR*, *ALK*, *ROS1*) (2-4). More recently, the advent of third generation TKIs also allowing the treatment of first or second generations resistance NSCLC patients, but unfortunately, also for these patients, several mechanisms of acquired resistance are now described (5).

In addition to oncogene addicted treatment strategies, the recent understanding of cancer immune evasion biological mechanisms lead to the implementation in clinical practice of new class of immunomodulatory agents able to reactivate host immune-response, leading to remarkably changed of first and second line therapeutic algorithms (6). In particular, for EGFR, ALK, and ROS1 wild-type patients, expressing ≥50% of PD-L1 on neoplastic cells, Pembrolizumab represents the best choice in first-line setting. Moreover, different therapeutic combination regimens (anti-PD-1/anti PD-L1 plus chemotherapy and anti-PD-1 plus anti-CTLA4) could become newer options also for non-oncogene addicted NSCLC patients expressing ≤50% of PD-L1 (6,7).

In this very exciting scenario, to find the right way for the right patients, the correct biomarkers assessment for optimal patient selection through the implementation of more sensitive and specific methodologies in association with integration among different biological sources of material (e.g., tissue, blood, exosomes) became the key weapon to minimize the adverse events and to improve the clinical outcome of NSCLC patients (8,9). Considering all together the papers published in the special issue "Targeted therapy and non-small cell lung cancer: a new era?" represent a critical point of view on well established therapeutic options and new perspectives in the very complex field of NSCLC patients management with also an interesting focus on communicational issues in the precision medicine era (10), to support the oncologist to select the best therapeutic approach for advanced NSCLC patients.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, *Translational Cancer Research* for the series "Targeted Therapy and Non-Small Cell Lung Cancer: A New Era?". The article did not undergo external peer review.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2018.12.36). The series "Targeted Therapy and Non-Small Cell Lung Cancer: A New Era?" was commissioned by the editorial office without any funding or sponsorship. UM and CR served as the unpaid Guest Editors of the series. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Malapelle U, Mayo de-Las-Casas C, Rocco D, et al. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. Br J Cancer 2017;116:802-10.
3. Karachaliou N, Fernandez-Bruno M, Jillian Bracht JW, et al. EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients. Transl Cancer Res 2019;8:S23-47.
4. Vavalà T, Mariniello A, Novello S. Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer. Transl Cancer Res 2019;8:S48-54.
5. Pisapia P, Rocco D, Pepe F, et al. EGFR exon 19 deletion switch and development of p.L792Q mutation as a new resistance mechanism to osimertinib: a case report and literature review. Transl Cancer Res 2019;8:S64-9.
6. Rocco D, Della Gravara L, Avellino A, et al. Immunotherapy as a targeted therapy in non-small cell lung cancer. Transl Cancer Res 2019;8:S70-5.
7. Listì A, Barraco N, Bono M, et al. Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer. Transl Cancer Res 2019;8:S55-63.
8. Reclusa P, Laes JF, Malapelle U, et al. EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy. Transl Cancer Res 2019;8:S76-8.
9. Mayo de las Casas C, Garzón-Ibañez M, Jordana-Ariza N, et al. Prospective analysis of liquid biopsies of advanced non-small cell lung cancer patients after progression to targeted therapies using GeneReader NGS platform. Transl Cancer Res 2019;8:S3-15.
10. Finocchiaro CY, Rota A, Barbieri V, et al. Listening Understanding and actiNG (lung): focus on communicational issue in thoracic oncology. Transl Cancer Res 2019;8:S16-22.

Umberto Malapelle



Christian Rolfo

Umberto Malapelle

Department of Public Health, University of Naples Federico II, Naples, Italy. (*Email: umberto.malapelle@unina.it*)

Christian Rolfo

Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA. (*Email: christian.rolfo@umm.edu*)

Submitted: 29 December 2018; Accepted for publication: 5 January 2019

doi: 10.21037/tcr.2018.12.36

View this article at: http://dx.doi.org/10.21037/tcr.2018.12.36

Cite this article as: Malapelle U, Rolfo C. Targeted therapy and non-small cell lung cancer: a new era! Transl Cancer Res 2019;8(Suppl 1):S1-S2. doi: 10.21037/tcr.2018.12.36